CD8A and neoplasm: In these conditions, tumor re-challenged mice, at an anatomical site different from the primary tumor, showed enhanced frequencies of circulating E7-specific IFN-γ-producing CD8+ T cells (Fig. 7C) and 90% of tumor rejection, remaining tumor-free until the end of the follow-up period (Fig.7F).